Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000368412 | SCV000344457 | pathogenic | not provided | 2018-01-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001376636 | SCV000941771 | pathogenic | Wolman disease | 2024-10-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser133*) in the LIPA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LIPA are known to be pathogenic (PMID: 23485521). This variant is present in population databases (rs756016704, gnomAD 0.004%). This premature translational stop signal has been observed in individuals with Wolman disease (PMID: 24832708, 28220406). ClinVar contains an entry for this variant (Variation ID: 289986). For these reasons, this variant has been classified as Pathogenic. |
Centre for Inherited Metabolic Diseases, |
RCV000801965 | SCV001554463 | pathogenic | Lysosomal acid lipase deficiency | 2021-04-07 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000801965 | SCV002060124 | pathogenic | Lysosomal acid lipase deficiency | 2021-11-08 | criteria provided, single submitter | clinical testing | NM_000235.2(LIPA):c.398delC(S133*) is a nonsense variant classified as pathogenic in the context of lysosomal acid lipase deficiency. S133* has been observed in cases with relevant disease (PMID: 11441129). Functional assessments of this variant are available in the literature (PMID: 11441129). S133* has been observed in population frequency databases (gnomAD: NFE 0.004%). In summary, NM_000235.2(LIPA):c.398delC(S133*) is a nonsense variant in a gene where loss of function is a known mechanism of disease, is predicted to disrupt protein function, and has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. |
Fulgent Genetics, |
RCV005003614 | SCV002813880 | pathogenic | Wolman disease; Cholesteryl ester storage disease | 2024-05-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000368412 | SCV005079967 | pathogenic | not provided | 2024-02-28 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 33726816, 26913919, 23485521, 11441129, Gashoot2024[case_report], 33857477, 30684275, 24832708, 28220406) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001376636 | SCV005204271 | pathogenic | Wolman disease | 2024-06-13 | criteria provided, single submitter | clinical testing | Variant summary: LIPA c.398delC (p.Ser133X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2e-05 in 251418 control chromosomes (gnomAD). c.398delC has been reported in the literature in multiple individuals affected with Lysosomal Acid Lipase Deficiency (Zschenker_2001, Poinsot_2016), including homozygotes. These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 33857477, 11441129). ClinVar contains an entry for this variant (Variation ID: 289986). Based on the evidence outlined above, the variant was classified as pathogenic. |
Natera, |
RCV000801965 | SCV001453548 | pathogenic | Lysosomal acid lipase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |